Big Pharma drug no match for ours: Zelira
Zelira Therapeutics’ share price almost tripled after it announced its diabetic nerve pain drug outperformed multi-billion dollar Big Pharma drug, Lyrica. Top line results demonstrated that Zelira’s proprietary ZLT-L-007 drug outperformed Lyrica by achieving a significant reduction in NRS pain scores, indicating a decrease in symptom severity. ZLT-L-007 was found to be safe and well-tolerated, … [Read more…]